Cargando…
Future perspectives on swine viral vaccines: where are we headed?
Deliberate infection of humans with smallpox, also known as variolation, was a common practice in Asia and dates back to the fifteenth century. The world’s first human vaccination was administered in 1796 by Edward Jenner, a British physician. One of the first pig vaccines, which targeted the bacter...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780603/ https://www.ncbi.nlm.nih.gov/pubmed/33397477 http://dx.doi.org/10.1186/s40813-020-00179-7 |
_version_ | 1783631534094286848 |
---|---|
author | Opriessnig, Tanja Mattei, Ashley A. Karuppannan, Anbu K. Halbur, Patrick G. |
author_facet | Opriessnig, Tanja Mattei, Ashley A. Karuppannan, Anbu K. Halbur, Patrick G. |
author_sort | Opriessnig, Tanja |
collection | PubMed |
description | Deliberate infection of humans with smallpox, also known as variolation, was a common practice in Asia and dates back to the fifteenth century. The world’s first human vaccination was administered in 1796 by Edward Jenner, a British physician. One of the first pig vaccines, which targeted the bacterium Erysipelothrix rhusiopathiae, was introduced in 1883 in France by Louis Pasteur. Since then vaccination has become an essential part of pig production, and viral vaccines in particular are essential tools for pig producers and veterinarians to manage pig herd health. Traditionally, viral vaccines for pigs are either based on attenuated-live virus strains or inactivated viral antigens. With the advent of genomic sequencing and molecular engineering, novel vaccine strategies and tools, including subunit and nucleic acid vaccines, became available and are being increasingly used in pigs. This review aims to summarize recent trends and technologies available for the production and use of vaccines targeting pig viruses. |
format | Online Article Text |
id | pubmed-7780603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77806032021-01-05 Future perspectives on swine viral vaccines: where are we headed? Opriessnig, Tanja Mattei, Ashley A. Karuppannan, Anbu K. Halbur, Patrick G. Porcine Health Manag Review Deliberate infection of humans with smallpox, also known as variolation, was a common practice in Asia and dates back to the fifteenth century. The world’s first human vaccination was administered in 1796 by Edward Jenner, a British physician. One of the first pig vaccines, which targeted the bacterium Erysipelothrix rhusiopathiae, was introduced in 1883 in France by Louis Pasteur. Since then vaccination has become an essential part of pig production, and viral vaccines in particular are essential tools for pig producers and veterinarians to manage pig herd health. Traditionally, viral vaccines for pigs are either based on attenuated-live virus strains or inactivated viral antigens. With the advent of genomic sequencing and molecular engineering, novel vaccine strategies and tools, including subunit and nucleic acid vaccines, became available and are being increasingly used in pigs. This review aims to summarize recent trends and technologies available for the production and use of vaccines targeting pig viruses. BioMed Central 2021-01-04 /pmc/articles/PMC7780603/ /pubmed/33397477 http://dx.doi.org/10.1186/s40813-020-00179-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Opriessnig, Tanja Mattei, Ashley A. Karuppannan, Anbu K. Halbur, Patrick G. Future perspectives on swine viral vaccines: where are we headed? |
title | Future perspectives on swine viral vaccines: where are we headed? |
title_full | Future perspectives on swine viral vaccines: where are we headed? |
title_fullStr | Future perspectives on swine viral vaccines: where are we headed? |
title_full_unstemmed | Future perspectives on swine viral vaccines: where are we headed? |
title_short | Future perspectives on swine viral vaccines: where are we headed? |
title_sort | future perspectives on swine viral vaccines: where are we headed? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780603/ https://www.ncbi.nlm.nih.gov/pubmed/33397477 http://dx.doi.org/10.1186/s40813-020-00179-7 |
work_keys_str_mv | AT opriessnigtanja futureperspectivesonswineviralvaccineswhereareweheaded AT matteiashleya futureperspectivesonswineviralvaccineswhereareweheaded AT karuppannananbuk futureperspectivesonswineviralvaccineswhereareweheaded AT halburpatrickg futureperspectivesonswineviralvaccineswhereareweheaded |